Zenas BioPharma, Inc.
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
ZBIO | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 852 WINTER STREET, SUITE 250, 2451 WALTHAM
- Website:
- https://zenasbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Zenas BioPharma is a clinical-stage, global biopharmaceutical company focused on the development and commercialization of immunology-based therapies for autoimmune diseases. The company aims to address significant unmet medical needs by advancing a portfolio of potentially transformative treatments. Its late-stage pipeline features two primary investigational drug candidates: obexelimab, a bifunctional monoclonal antibody designed to suppress B cell activity, and orelabrutinib, a selective oral small molecule BTK inhibitor. Zenas BioPharma's strategy includes in-licensing and developing innovative drug candidates to build a leading immunology-focused portfolio.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Zenas BioPharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Zenas BioPharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Zenas BioPharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
